Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale by Zang, Yuguo et al.
Towards Protein Crystallization as a Process Step in
Downstream Processing of Therapeutic Antibodies:
Screening and Optimization at Microbatch Scale
Yuguo Zang
1*, Bernd Kammerer
2¤, Maike Eisenkolb
1, Katrin Lohr
3, Hans Kiefer
2
1Institute of Pharmaceutical Biotechnology, Biberach University of Applied Sciences, Biberach, Germany, 2Biberach University of Applied Sciences, Biberach, Germany,
3Boehringer Ingelheim Pharma GmbH&Co. KG., Biberach, Germany
Abstract
Crystallization conditions of an intact monoclonal IgG4 (immunoglobulin G, subclass 4) antibody were established in vapor
diffusion mode by sparse matrix screening and subsequent optimization. The procedure was transferred to microbatch
conditions and a phase diagram was built showing surprisingly low solubility of the antibody at equilibrium. With up-scaling
to process scale in mind, purification efficiency of the crystallization step was investigated. Added model protein
contaminants were excluded from the crystals to more than 95%. No measurable loss of Fc-binding activity was observed in
the crystallized and redissolved antibody. Conditions could be adapted to crystallize the antibody directly from
concentrated and diafiltrated cell culture supernatant, showing purification efficiency similar to that of Protein A
chromatography. We conclude that crystallization has the potential to be included in downstream processing as a low-cost
purification or formulation step.
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Introduction
Therapeutic monoclonal antibodies (mAbs) were introduced
into the market in 1986. Since then, processing technologies for
this class of therapeutics have seen enormous progress as
exemplified by recombinant cell lines producing titers in the
range of 10 grams per liter of cell culture. Downstream processing
technology currently relies heavily on protein A chromatography,
a fast and highly selective capturing step, followed by additional
chromatographic procedures such as ion exchange or hydrophobic
interaction chromatography. Although the purity of mAb achieved
after Protein A chromatography usually exceeds 90%, further
purification steps are required to meet the exceptionally high
purity targets of biopharmaceuticals. The major drawback of
chromatographic procedures is the high cost of adsorption media,
which can amount to more than ten thousand US dollar per liter
of Protein A resin. Therefore, more economic procedures able to
replace at least one chromatographic operation are subject to
extensive research.
Protein crystallization, which has been mostly applied in protein
structure analysis, has been recognized in principle as a method of
protein purification [1,2]. Within a crystal, protein molecules form
a regular lattice able to exclude other proteins as well as misfolded
protein molecules of the same type. Therefore, as routinely applied
to small molecules, crystallization can also be used as a cheap and
scalable purification procedure [3]. Earlier work has demonstrated
the feasibility of protein purification by crystallization e.g. for an
industrial lipase [4] or the model protein ovalbumin [5]. However,
the only biopharmaceutical routinely crystallized at industrial scale
and with excellent recovery yields is insulin [6]. Insulin is a small
and extraordinarily stable peptide able to refold easily into its
native structure even after exposure to organic solvents. It is
crystallized late in the purification sequence where most of the
impurities have already been removed [4].
Additional benefits of protein crystallization from a formulation
perspective are the higher stability of crystalline proteins in
comparison to protein solutions, making crystalline formulations
an attractive alternative with potentially longer shelf life, and the
possibility to control delivery of a protein by making use of crystal
dissolution kinetics [7]. The latter has been investigated extensively
in the context of insulin formulations [8].
For immunoglobulin, the use of this technique as a means of
purification or formulation is not yet a routine procedure. Several
authors studied phase behavior of mAbs with the goal to identify a
rational approach leading to crystallization conditions [9–11]. The
work has been complicated by the fact that in addition to
crystallization other phenomena such as precipitation, phase
separation and the formation of gel-like phases can occur that
kinetically trap the system far from equilibrium and as a
consequence reduce the yield of crystalline protein or inhibit
crystal formation completely.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25282In our study, we chose an IgG4 mAb that readily crystallizes
under a range of conditions, allowing us to optimize the procedure
with respect to mass and activity recovery and degree of purity.
Focusing on a simple system composed of solvent and crystals, we
were able to identify the solubility limit in a phase diagram and use
this as the starting point for up-scaling to a process step
conforming to GMP requirements. The aim of this work is to
show how initial crystallization conditions can be improved and
optimized to result in a process step that delivers high purity and
high recovery. We want to point out however, that for any
individual antibody, those initial conditions have to be identified
by screening. There is yet no method available that allows
predicting crystallization conditions from protein sequence or
general physico-chemical parameters. Nor can crystallization
conditions be transferred from one protein to another even if
they are very closely related in sequence [12]. The osmotic virial
coefficient B22, which has been shown to often adopt values within
a certain range (‘‘crystallization slot’’) under conditions promoting
protein crystallization [13], has not proven to become a general
predictor for proteins difficult to crystallize [10] [14].
Materials and Methods
Antibody
Clarified cell culture supernatant of a CHO derived cell line
secreting monoclonal IgG4 type antibody mAb04c as well as
Protein A-purified mAb04c were kindly provided by Boehringer
Ingelheim Pharma GmbH (Biberach, Germany).
Crystallization technique
Wizard
TM I, II, III Crystal Screen kits were from Emerald
BioSystems (Bainbridge Island, US). Basic and Extension Kits
were from Sigma (Taufkirchen, Germany).
For protein crystallization, both vapor diffusion and microbatch
techniques were utilized. The methods were performed according
to Bergfors [15]. 96 well crystallization plates from Corning
(Amsterdam, The Netherlands) and Crystalbridge
TM (45 ml) from
Greiner bio-one (Germany) were used for sitting drops. 24 wells
plate (Greiner bio-one) were used for hanging drop and 60 wells
plate (Greiner bio-one) for microbatch crystallization. The protein
solution was filtered through 0.2 mm filter (Sartorius, Germany)
before crystallization.
Concentration and buffer exchange
Protein A-purified mAb was dialyzed overnight against 20 mM
Tris buffer pH 7.0 at 4uC, and was then concentrated to the
desired concentration with Vivaspin
TM 500 centrifugal filter
(30 kDa MWCO, Sartorius) by centrifugation (15000 g, 4uC).
Cell culture supernatant was diafiltrated using 7 volumes of
20 mM Tris, 50 mM Histidine, pH 7, and 30 kDa MWCO
membrane cassettes (Hydrostat, Sartorius, Germany). Next,
mAb was concentrated with Vivaspin
TM 500 to the required
concentration.
Concentration of purified mAb was determined photometrically
at 280 nm using a NanoDropH 1000 (Thermo Scientific, US)
photometer, whereas mAb concentration of culture supernatant
was measured by size exclusion HPLC (SE-HPLC) on a Tosoh
TSK-GEL 3000 SWXL column at 25uC. HPLC system was
HP1100 from Agilent (Waldbronn, Germany). Elution buffer was
0.05 M Tris/0.15 M NaCl, pH 7, the flow rate was 1 ml/min.
ChromeleonH software (Dionex, Sunnyvale, US) was applied for
chromatogram recording. Protein was detected at 225 nm and
integrated elution peaks were compared to a mAb standard
calibration curve.
Purity of mAb was estimated by SE-HPLC and by SDS-PAGE
on 12.5% Laemmli gels. SDS gels were stained with Coomassie
Blue or silver.
Distinction of crystals and amorphous precipitate
Crystals and amorphous precipitate were distinguished through
birefringence using a microscope (Nikon Eclipse 80i, Du ¨sseldorf,
Germany) equipped with polarizing filters. Birefringent protein
crystals change color upon rotation of the polarizing filter, while
amorphous precipitate does not show this behavior.
Harvest of protein crystal
Crystals were separated from the mother liquor by 10 min
centrifugation at 4uC and 10,000 g and washed 3 times with
reservoir solution, each volume of the wash reservoir being the
same as that of the original sample of crystal suspension. The
crystals were redissolved in 100 mM sodium acetate pH 4.0, and
stored at 4uC for further analysis.
Determination of phase diagram
The apparent phase diagram was obtained from microbatch
experiments in 60 well plates at room temperature (about 22uC).
1.5 mL of protein solution were mixed with an equivalent volume
of crystallization reagent and covered by paraffin oil (Hampton
Research, Aliso Viejo, US). Experiments were monitored visually
under microscope over a period of five days. No visual changes
were detected starting from day three.
In the metastable zone spontaneous nucleation does not occur,
and therefore equilibrium cannot be reached through the growth
of crystals starting from a supersaturated solution. The solubility
limit of mAb04c was therefore measured by dissolving crystals in a
protein-free solution until equilibrium reached. MAb04 was first
crystallized as controlled by microscopy at 8 mg/ml protein, 8%
w/v PEG 8000, 0.2 M Ca(OAc)2, 0.1 M Imidazol, pH 7 using
microbatch process. Crystals were harvested, homogenized with
Seed Bead
TM (Hampton Research), and resuspended in deionized
water. 20 ml Aliquots of this suspension were added to 1.5 ml
centrifuge tubes. Subsequently, 100 ml of precipitant solution as
above, but with varying PEG 8000 concentrations was added to
each aliquot. The amount of crystallized protein was in excess so
that crystals would not dissolve completely. After five days mixing
in a Thermomixer Campact (RT, 300 RPM, Eppendorf,
Germany), the protein concentration in the supernatant was
determined via A280 measurement in a NanoDrop photometer
following 10 min centrifugation at 10,000 g. Control experiments
showed that equilibrium had been attained at this time.
Binding activity measurement
The functional integrity of the Fc portion of crystallized mAb
was confirmed by binding to immobilized Protein A on a BiacoreH
T100 SPR instrument (GE Healthcare, Germany) as described by
the manufacturer.
Spiking experiments with protein contaminations, DNA
and bacteriophage
Host cell proteins (HCPs), virus and DNA are critical impurities
in the production of biopharmaceuticals. Therefore, spiking
experiments using model protein impurities, genomic DNA and
bacteriophage T7 as a virus model were carried out.
For HCP spiking, purified mAb (8.6 mg/ml) was mixed with
lysozyme (14.3 kDa, 10 mg/ml, Fluka, Schwitzerland) or BSA
(bovine serum albumin, 66 kDa, 10 mg/ml, Carl Roth, Germany)
and then crystallized by sitting drop vapor diffusion. Precipitant
mAb Purification by Crystallization
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25282solution was 10% w/v PEG 8000, 0.2 M Ca(OAc)2, 0.1 M
Imidazol, pH 7 as above.
For DNA and phage spiking, DNA at a concentration of 25 mg
DNA/mg mAb or phage at a concentration of 6.4610
7 PFU
(Plaque Forming Unit)/mg mAb were added to mAb04c.
Crystallization was carried out as above.
Bacteriophage T7 and E. coli strain B were kindly provided by
A. Kuhn (Hohenheim University, Germany). Bacteriophage
concentration was determined by plaque counting following the
online protocol [16]. E. coli was cultured in LB-Medium pH 7.5.
Phage was diluted in 0.85% phosphate buffered saline (PBS buffer:
8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 KH2PO4,
pH 7.4). Agar plates contained 20 g pepton, 3.5 g NaCl, 15 g
agar, 1.5% w/v glucose, 6.75 mM Na2HPO4, 8 ml 1% w/v
aniline blue (filtered through 0.2 mm sterile filter) per liter. Soft top
agar was 7 g agar per liter. All solutions were autoclaved.
DNA concentration was measured using a 96 wells microplate
(Greiner bio-one) SYBRH Green I (Invitrogen, Germany) assay
[17]. Chromosomal DNA was from salmon sperm (Fluka,
Germany). SpectraMaxH microplate reader was from Molecular
Devices (US). Excitation: 488 nm/Emission: 520 nm.
Results and Discussion
Seven hits (microcrystals or crystals) were found in sparse matrix
screening using commercial screen kits. After 3 repetition tests
with the 7 conditions found, the most robust condition (10% w/v
PEG 8000, 0.2 M Ca(OAc)2, 0.1 M Imidazol, pH 7) was chosen
as the starting point of a phase diagram. Crystals obtained were
coffin-shaped structures (Figure 1). Mechanical rigidity, as
qualitatively assessed by micromanipulation using ‘‘Crystal tools’’
(Hampton Research) under microscope, was high compared to
‘‘needles’’ found in other screening experiments. When the seeding
stock was prepared (see above) omission of the ‘‘Seed bead’’, acting
as a ball mill, even vigourous vortexing resulted in a preparation
that contained relatively large crystals and fragments. We
therefore expect that those crystals will not fragment extensively
under mechanical stress, e.g. in a stirred crystallizer, and will be
suitable for subsequent solid-liquid separation. Protein solubility
was studied as a function of the concentrations of protein and PEG
8000 in 0.1 M Imidazol 0.2 M calcium acetate pH 7 at RT
(Figure 2). The solubility of mAb decreased with increasing
precipitate concentration. Crystals were observed at PEG 8000
concentrations exceeding 5% (w/v). In the protein concentration
range between 10 and 14 mg/ml, there was a broad crystallization
region between 5 and 9% PEG 8000.
However, this method does not provide the solubility limit, as
crystallization does not occur spontaneously in the metastable
region where kinetic effects prevent nucleation [12]. Therefore,
the solubility limit was determined by preparing saturated
solutions in equilibrium with crystalline protein and measuring
the protein concentration in the supernatant. The solubility limit
(solid line in Figure 2) was found to be located far away from the
crystallization zone at protein and precipitant concentrations at
least one order of magnitude below the limit of spontaneous
crystallization. This result indicates that mAb04c crystallizes
spontaneously only at high supersaturation.
The crystallization of mAb04c in the presence of contaminating
protein was examined by spiking with model protein impurities as
described by Judge et al [5]. Crystals appeared after 2 days and the
crystal shape was indistinguishable from crystals of non-contam-
inated mAb04c. Crystals were harvested after 5 days and then
redissolved in 100 mM Sodium Acetate pH 4. On SDS-PAGE,
neither Lysozyme nor BSA still present in the mother liquor was
detected in the redissolved mAb crystals (Figure 3, lanes 3 and 6).
The only bands detectable resulted from the original mAb protein
(IgG light and heavy chains), plus a band probably resulting from
partially degraded heavy chain. The contaminants Lysozyme and
BSA were only present in the mother liquor (lanes 2 and 5) and in
the wash solutions (lanes 4 and 7). Silver staining is reported to
Figure 1. Micrograph of crystals of mAb04c under polarized light. 3 ml microbatch. Conditions: 1.5 ml 20 mg/ml mAb04c in 20 mM Tris,
50 mM Histidine, pH 7 plus 1.5 ml 12% (w/v) PEG 8000, 0.4 M calcium acetate in 0.2 M Imidazol, pH 7, RT. The broken crystal (intentionally) indicates
that the dimension of crystal is about 100,150 mm610,20 mm610,20 mm.
doi:10.1371/journal.pone.0025282.g001
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more than 90% of the protein contaminations had been removed.
With the success of the HCP spiking test, we attempted to purify
mAb04c from the culture supernatant through one-step crystal-
lization. The supernatant was conditioned and concentrated by
diafiltration/ultrafiltration and centrifugation as described above.
The volume of crystallization suspension was scaled up from 2 ml
to 40 ml in a Crystalbridge
TM (20 ml protein solution plus 20 ml
reservoir). The reservoir was also scaled correspondingly to 20 ml
to keep the ratio constant.
Similar to results of the HCP spiking test, crystals became visible
after 2 days (Figure 4). After 5 days the harvested crystals were
redissolved in 20 ml 100 mM Sodium Acetate pH 4. On SDS-
PAGE using Coomassie staining (Figure 5), the concentration of
contaminating proteins was considerably reduced (lane 2). A
sample of IgG purified by protein A chromatography is shown as a
benchmark reference (lane 3). The purity and amount of mAb in
each fraction was then accessed by HPLC-SEC (Table 1). Before
crystallization, the purity of mAb04c in solution (8.3 mg/ml in
20 ml supernatant) was 42% of total protein according to peak
integration. The analysis of redissolved crystals (2.6 mg/ml mAb
in 20 ml buffer) showed that no significant oligomer arose from
crystallization (Figure 6). The purity was increased significantly to
90% of total protein. Still, only 31.3% of the mAb originally
present in the culture supernatant was recovered in crystals, while
the larger portion (67.5%) was still found in the crystallization
supernatant. In comparison, the yield of crystalline mAb04c that
had undergone a prior protein A purification was 95% with no
detectable product in the mother liquor.
The binding ability of mAb04c to protein A before and after
crystallization was determined via BiacoreH. The association rate
constants (ka) were compared to evaluate a potential affinity loss.
Before crystallization, ka was determined to 3.35610
6 L/(mol*s),
while after crystallization ka was 4.81610
6 L/(mol*s). Apparently,
crystallization had no influence on the affinity of the Fc-Region for
protein A.
In spiking experiments, T7 bacteriophage and chromosomal
DNA were added to the mAb solution before crystallization in
order to challenge the ability of the crystallization process to
remove non-protein impurities. Results are summarized in Table 2.
LRV (Log reduction value) was 1.4 for DNA and 2.2 for T7
phage.
In the present work, we examined the possibility of establishing
crystallization as a process step for purification and formulation of
a monoclonal antibody. High yields were achieved when
crystallization was introduced after chromatographic purification,
but not when conditioned cell culture supernatant was used as
starting material. Interestingly, crystallization from culture super-
natant was nevertheless possible and resulted in efficient removal
of contaminants.
We frequently observed that within the crystallization region
(area labeled by triangles in Figure 2), protein initially precipitated
directly after mixing (Figure 7a), while crystals were detectable
under the microscope only after a 3–4 hour lag period (Figure 7b
& 7c). This effect is known from literature. Even when the
crystalline form of protein is more stable than its amorphous form,
slow nucleation can delay the formation of crystals with respect to
amorphous precipitate [18,19]. Precipitate concentration will then
decrease at the same time as crystals grow. Two models have been
proposed to explain the growth of crystals from precipitates: phase
transition and Oswald ripening [20]. Phase transition is a process
where crystals form at the expense of a solid amorphous phase,
whereas Oswald ripening describes growth of a few crystals at the
expense of many microcrystals [21]. Ng et al. [20] reported that
both processes can occur simultaneously. Unfortunately, the
birefringence method described above is not applicable to
microcrystals smaller than the microscope resolution limit. In lack
of a method distinguishing between amorphous precipitate and
microcrystals, we could not decide which of the above processes
was dominant.
To our knowledge, this is the first determination of the solubility
limit at equilibrium for an IgG protein. Ahamed et al. [9] describe
Figure 2. Phase diagram of mAb04c with PEG 8000 as precipitant. Buffer: 0.1 M imidazol, 0.2 M calcium acetate, pH 7.0, RT.
doi:10.1371/journal.pone.0025282.g002
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crystals formed. In comparison to their findings, we found a much
lower solubility limit. This could of course be attributed to using a
different protein, but Ahamed et al. point out that they would
expect a lower solubility limit at equilibrium, i.e. in the presence of
crystals as opposed to precipitate. The same antibody was studied
by Lewus et al. [10] recently, and crystallization conditions were
now identified at a different pH. However, here the solubility limit
was not determined unequivocally as concentrations measured in
the supernatant decreased over the course of 2 months (Fig. 4 of
above reference). The large gap found in our experiments between
equilibrium solubility and zone of spontaneous crystallization
appears unexpected at first sight, but might be a feature of IgGs in
general. However, similar studies on other model antibody systems
will have to be performed before this view can be corroborated.
From a practical point of view, our result means that in a
continuous process using heterogeneous nucleation, protein should
be crystallizable at much lower protein concentration such as
2 mg/ml and at precipitant concentrations of 7% PEG 8000 or
even lower.
Removal of protein contaminations and virus was successful and
comparable to Protein A chromatography. DNA removal however
was marginal. This may be due to adsorption of DNA to the
crystal surface by electrostatic interaction (mAb04c is positively
charged at the pH of crystallization). We found that reducing the
spiking concentration to 2.5 mg DNA/mg mAb, resulted in
0.35 mg DNA/mg mAb (data not shown), i.e. in an even lower
LRV.
Recovery yield of crystallized mAb that had undergone prior
protein A purification reached 95%. This is expected when
crystallization conditions are far above the solubility limit as
revealed by the phase diagram. However, such high yields could
not be achieved when cell culture supernatant was subjected to
crystallization. Here the recovery of ,30% indicated that either
solubility of mAb had dramatically increased due to other
compounds present in the culture supernatant, or crystallization
had simply slowed-down. Microscopic examination indicated that
onset of crystal formation was significantly delayed when culture
supernatant was used instead of purified antibody: in the latter
case, crystals could already be detected after 10 hrs, whereas the
same process took 48 hrs starting from culture supernatant. Still,
crystal shapes were similar in both cases.
Figure 3. SDS-PAGE of HCP spiking experiment. Silver-staining.
Lanes: (1) mAb04c, standard; (2) mother liquor with mAb04c and
lysozyme; (3) washed mAb04c crystals from mother liquor with
lysozyme; (4) the supernatant from the crystallization with lysozyme;
(5) mother liquor with mAb04c and BSA; (6) washed mAb04c crystals
from mother liquor with BSA; (7) the supernatant from the crystalliza-
tion with BSA.
doi:10.1371/journal.pone.0025282.g003
Figure 4. Micrograph of crystalline mAb04c crystallized from
clarified culture supernatant. Crystallization condition: sitting drop.
Reservoir: 0.1 M imidazol, 0.2 M calcium acetate, 9% w/v PEG 8000.
20 mL clarified culture supernatant (8.3 mg/ml mAb04c) plus 20 ml
reservoir, RT. Scale bar 100 mm.
doi:10.1371/journal.pone.0025282.g004
Figure 5. Coomassie blue stained none-reducing SDS-PAGE of
mAb04c before and after crystallization or protein A purifica-
tion. 7 mg of IgG was loaded per lane. Lanes: (1) clarified mAb04c
culture supernatant; (2) washed mAb04c crystals, redissolved in
100 mM sodium acetate pH 4.0; (3) mAb04c, purified via protein A
chromatography.
doi:10.1371/journal.pone.0025282.g005
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25282Figure 6. SE-Chromatogram of the sample before and after crystallization. Elution buffer: 0.05 M Tris/0.15 M NaCl, pH 7; flow rate: 1 ml/
min; wavelength: 225 nm. (A) Clarified mAb04c culture supernatant. Peak 3: mAb04c, 8.42 min; Peak 4: Contaminating Protein, 9.98 min; Peak 5:
Histidine in buffer, 12.19 min. (B) washed mAb04c crystals, redissolved in 100 mM sodium acetate pH 4.0. Peak 2: mAb04c, 8.43 min.
doi:10.1371/journal.pone.0025282.g006
Table 1. Purity and Recovery of crystallized mAb04c.
Fraction Amount of mAb04c (mg) Recovery (%) Purity (%, estimated)
Clarified culture supernatant 166 100 42
washed mAb 04c crystals
* 52 31.3 90
supernatant from the crystallization 112 67.5 10
*Protein redissolved in 100 mM sodium acetate pH 4.0.
doi:10.1371/journal.pone.0025282.t001
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formation. The nucleation rate depends in principle on the
solubility of the protein, the degree of supersaturation and the
interfacial free energy (c) between solute and solution [22]. The
first two contributions are not expected to be significantly
influenced by the presence of impurities. As for the interfacial
free energy, from thermodynamic aspect, an increase of the
nucleation rate should be observed when impurities are present in
the solution [22], because any adsorption onto the nucleus
decreases c [23]. However, kinetically, adsorbing impurities can
keep the nucleus at a subcritical size [22]. The nucleation rate
hence can be drastically reduced. It was reported that impurities
present at 10
25 mol/L can decrease the nucleation rate by ten
orders of magnitude [24]. Biostelle et al. [22] point out that there
is a competition between the adsorption kinetics of the impurities
and the adsorption and integration kinetics of the solute, hence, a
longer nucleation time is needed.
Moreover, this competition may further affect the growth of
crystals when nuclei develop and begin to transform into crystals.
Impurities can adsorb to the surface of the growing crystal, inhibit
the addition of free molecules and thereby decrease the growth
rate. Because of the negative effect of impurities in both stages of
crystallization, the observed delay in mAb04c crystal formation in
the presence of contaminating protein was not unexpected. In our
work we did not study which stage was prone to be affected by the
presence of impurities.
A low recovery rate (31.3%) was observed, when mAb04c was
crystallized from culture supernatant. In a future scaled-up
process, nucleation and crystallization rates will have to be
controlled e.g. by seeding, feeding protein during crystallization or
Table 2. Results of DNA and phage spiking.
Spiking concentration Concentration in re-dissolved crystals LRV
T7 phage [PFU/mg mAb] 6.4610
7 4.5610
5 2.2
DNA [mg/mg mAb] 25 1.1 1.4
doi:10.1371/journal.pone.0025282.t002
Figure 7. Time course of microbatch crystallization. Protein: 8 mg/ml mAb04c, crystallization buffer: 8% (w/v) PEG 8000, 0.2 M calcium acetate
0.1 M imidazol, pH 7.0, RT. Time after mixing: (A) 0 hrs, (B) 2 hrs, (C) 10 hrs, (D) 70 hrs. Scale bar 100 mm.
doi:10.1371/journal.pone.0025282.g007
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be subject to significant improvement when working at larger
scale.
Conclusion
Protein crystallization has the potential to be introduced as a
purification step in downstream processing of mAbs, although our
present results so far show that it will likely be more useful in a
later purification step and not in initial capturing of the product.
Here we demonstrate purification of a monoclonal antibody in a
single crystallization step from clarified cell culture supernatant to
.90% purity, though with yet unsatisfactory yield. Aggregate
formation was negligible as shown by SE-HPLC and binding
activity to Protein A was not affected by crystallization. The
current crystallization time of several days required to reach
equilibrium is partly due to the shortcomings of vapor diffusion
and should be subject to considerably improvement in a seeded
batch process. Current work is focused on up-scaling and
optimization of the process with respect to higher yields. We are
well aware that at present only a handful of intact IgGs have been
successfully crystallized and that there is no generic method
available to identify crystallization conditions rapidly for new
antibodies. However, the recent results of Lewus et al. [10], who
were able to crystallize an antibody where previously no
crystallization conditions have been found [9], are encouraging.
More work on a larger set of target mAbs will have to be done
before the usefulness of this method can be evaluated in a broader
context.
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